Physician profile
Angel Keller
NPI 1487072096
$927.54
in general payments reported to CMS, 2019-2025
21 companies · $85.05 in 2025
The $85.05 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $285 · 2023: $292 · 2024: $130 · 2025: $85.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $115.20 | 2024 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $80.99 | 2024-2025 | |
| Averitas Pharma INC. | $80.38 | 2023 | Qutenza |
| Axsome Therapeutics, INC. | $77.47 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $73.22 | 2022 | |
| Biodelivery Sciences International, INC. | $67.21 | 2021 | |
| Grt US Holding, INC. | $67.13 | 2022 | |
| Collegium Pharmaceutical, INC. | $54.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.85 | 2022 | |
| Organogenesis INC. | $50.87 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.47 | 2023 | Rexulti, Abilify Maintena |
| Impel Pharmaceuticals INC. | $22.53 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.76 | 2023 | Jornay Pm |
| Spr Therapeutics, INC | $18.68 | 2025 | Sprint Pns System |
| Indivior INC. | $18.59 | 2023 | Perseris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.09 | 2023 | Belsomra |
| Pfizer INC. | $17.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.16 | 2023 | Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $16.94 | 2023 | Ingrezza |
| Alkermes, INC. | $16.60 | 2023 | Aristada, Lybalvi |
| Daiichi Sankyo INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.